Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Planning for human papillomavirus (HPV) vaccination in sub-Saharan Africa: a modeling-based approach.

Tracy JK, Schluterman NH, Greene C, Sow SO, Gaff HD.

Vaccine. 2014 May 30;32(26):3316-22. doi: 10.1016/j.vaccine.2014.03.067.

PMID:
24731734
2.

Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.

Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I.

Vaccine. 2013 Dec 29;31 Suppl 5:F60-72. doi: 10.1016/j.vaccine.2012.07.093.

PMID:
24331749
3.

Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).

Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M.

Vaccine. 2013 Dec 30;31 Suppl 6:G65-77. doi: 10.1016/j.vaccine.2012.06.096.

PMID:
24331822
4.

Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.

Gomez JA, Lepetic A, Demarteau N.

BMC Public Health. 2014 Nov 26;14:1222. doi: 10.1186/1471-2458-14-1222.

5.

Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.

Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.

Vaccine. 2015 May 7;33 Suppl 1:A167-73. doi: 10.1016/j.vaccine.2014.12.067.

PMID:
25919157
6.

Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.

Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S.

Vaccine. 2015 May 7;33 Suppl 1:A135-42. doi: 10.1016/j.vaccine.2014.12.031.

PMID:
25919154
8.

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.

Jit M, Brisson M, Portnoy A, Hutubessy R.

Lancet Glob Health. 2014 Jul;2(7):e406-14. doi: 10.1016/S2214-109X(14)70237-2.

9.

Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.

Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ.

Vaccine. 2013 Dec 31;31 Suppl 7:H71-9. doi: 10.1016/j.vaccine.2013.04.086.

PMID:
24332299
10.

An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.

Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, Qiao YL, Jamison DT, Kim JJ.

Vaccine. 2015 Jun 4;33(24):2830-41. doi: 10.1016/j.vaccine.2015.02.052.

11.

A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.

Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, Broutet N.

BMC Med. 2012 Nov 13;10:136. doi: 10.1186/1741-7015-10-136.

12.

Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.

Li X, Stander MP, Van Kriekinge G, Demarteau N.

BMC Infect Dis. 2015 Dec 11;15:566. doi: 10.1186/s12879-015-1295-z.

13.

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.

Vaccine. 2008 Jul 29;26(32):4080-93. doi: 10.1016/j.vaccine.2008.04.053.

PMID:
18550229
14.

Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China.

Liu YJ, Zhang Q, Hu SY, Zhao FH.

BMC Cancer. 2016 Feb 26;16:164. doi: 10.1186/s12885-016-2207-3.

15.
16.

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.

Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N.

Vaccine. 2014 Feb 3;32(6):733-9. doi: 10.1016/j.vaccine.2013.11.049.

17.

Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.

Kiatpongsan S, Kim JJ.

PLoS One. 2014 Sep 8;9(9):e106836. doi: 10.1371/journal.pone.0106836.

18.

Cost-effectiveness of HPV vaccination in Belize.

Walwyn L, Janusz CB, Clark AD, Prieto E, Waight E, Largaespada N.

Vaccine. 2015 May 7;33 Suppl 1:A174-81. doi: 10.1016/j.vaccine.2014.12.042.

PMID:
25919158
19.

Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.

Quentin W, Terris-Prestholt F, Changalucha J, Soteli S, Edmunds WJ, Hutubessy R, Ross DA, Kapiga S, Hayes R, Watson-Jones D.

BMC Med. 2012 Nov 13;10:137. doi: 10.1186/1741-7015-10-137.

20.

Estimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and cervical cancer incidence in Mali.

Tracy L, Gaff HD, Burgess C, Sow S, Gravitt PE, Tracy JK.

Clin Infect Dis. 2011 Mar 1;52(5):641-5. doi: 10.1093/cid/ciq190.

Items per page

Supplemental Content

Support Center